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OBJECTIVES: To compare dosing and treatment outcomes in
patients with cancer receiving epoetin alfa (EPO) and darbepo-
etin alfa (DARB). METHODS: Records across several clinical
and administrative data systems from adults receiving care in
outpatient VA practice settings were reviewed. Eligible patients
were required to have a cancer diagnosis, be ≥18 years, and have
a record of treatment with EPO or DARB for anemia (hemo-
globin (Hb) £11g/dL). RESULTS: A total of 2159 patients (1267
EPO, 892 DARB) were identiﬁed from November 2002–August
2003. Baseline characteristics such as age, gender, weight, tumor
type, percent receiving chemotherapy, baseline Hb, ECOG
status, transfusion use, and iron supplementation across groups
were all similar. Mean treatment duration was approximately 9
weeks (EPO: 57 days, DARB: 68 days). Mean weekly doses were:
EPO 35,337IU, DARB 108mcg. Mean cumulative doses were:
EPO 286,040IU, DARB 1036mcg. Based on average wholesale
price (AWP, Red Book 2003), weekly and cumulative treatment
costs were lower for EPO (EPO: $472/week, $3820/episode;
DARB: $539/week, $5170/episode; respectively). Hb change
from baseline independent of observed transfusion was signiﬁ-
cantly greater for EPO compared to DARB at all assessments
(Wk 4: 0.56 vs. 0.33g/dL, p < 0.0001; Wk 8: 0.76 vs. 0.46g/dL,
p < 0.0001; Wk 12: 0.93 vs. 0.64g/dL, p < 0.0001; respectively).
Cumulative hematologic effect, assessed by area under the Hb
change curve, was also greater for EPO (7.2 vs. 4.5g/dL). CON-
CLUSIONS: Results show greater early and overall hematologic
outcomes with EPO compared to DARB at lower treatment costs
suggesting dominance.
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OBJECTIVES: Diarrhea is a signiﬁcant dose-limiting toxicity
associated with chemotherapy treatment among cancer patients.
The objective of this study was to describe the demographic, clin-
ical, and management pattern characteristics of patients who
experience chemotherapy-induced diarrhea (CID) and assess the
impact of CID on resource utilization. METHODS: We con-
ducted a retrospective chart review of 378 cancer patients, d18
years, who experienced diarrhea during their chemotherapy
treatment between 2000 and 2003 from 25 community oncol-
ogy centers throughout the US. Demographic characteristics,
severity of diarrhea, and changes to chemotherapy treatment due
to diarrhea were evaluated using descriptive analysis. Compar-
isons of planned chemotherapy therapy versus actual chemother-
apy received by patients due to diarrhea and impact of CID on
anti-diarrheal medications, inpatient hospitalization and outpa-
tient visits were examined. RESULTS: Patients enrolled were
mostly white (80%) and middle-aged (mean 67 years). The most
common chemotherapy regimen received was 5-ﬂuorouracil
intravenous push + leukovorin (27%). There was a mean of 3.9
diarrheal episodes per patient. Patients who experienced CID
underwent signiﬁcant changes in their chemotherapy treatment,
including dose reductions (45%), delays in therapy (71%), and
reduction in dose intensity (64%). Treatment with anti-diarrheal
medications was done largely at home (74.9%) followed by
during ofﬁce visits (29.6%). Forty-four percent (n = 166) of the
study population had at least one CID related outpatient visit.
Mean number of outpatient visits for CID per patient was 2.5 +
2.5. Fifty-six patients (14.8%) experienced a CID-related hospi-
talization during the study time frame. CONCLUSIONS: The
study results showed that a signiﬁcant number of patients expe-
riencing CID required changes (usually reductions) to their
chemotherapy treatment, which may ultimately impact patient
clinical outcomes. CID also had a substantial impact on resource
utilization, which may translate into a considerable economic
burden.
PCN3
POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED
IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18
Goldie S1, Kohli M2, Grima D2,Weinstein MC1,Wright T3, Bosch F4,
Franco E5
1Harvard School of Public Health, Boston, MA, USA; 2Innovus
Research Inc, Burlington, ON, Canada; 3Columbia University, New
York, NY, USA; 4Institut Catala D’Oncologia, Barcelona, Spain; 5McGill
University, Montreal, QC, Canada
OBJECTIVES: To assess the comparative clinical beneﬁts asso-
ciated with HPV 16/18 vaccination when different assumptions
are made about the duration of efﬁcacy and the natural history
of detectable HPV 16/18 in women over 30. METHODS: A
computer-based model of cervical cancer simulates HPV 16/18
vaccination in a cohort of 12 year olds. We evaluated the impact
of waning after 5, 10, and 15 years on the effectiveness of a
vaccine that prevents 90% of persistent HPV 16/18 using alter-
native assumptions about the relative proportion of HPV infec-
tions in women over the age of 30 attributable to new acquisition
of HPV versus reactivation of latent or previously acquired HPV.
RESULTS: When we assumed that 50% of HPV infections in
older women are attributable to new acquisition of HPV, the
overall reduction in cancer varied from 54% with no waning, to
26%, 31%, and 36%, with waning after 5, 10, and 15 years,
respectively. As the proportion of persistent HPV infections
attributable to new (versus latent) infections was varied from
75% to 25% the overall reduction in cancer with waning at 5
years ranged from 16% to 36%; at 10 years ranged from 21%
to 41%, and at 15 years ranged from 28% to 48%. CONCLU-
SION: There are dramatic differences in the relative effects 
of waning when adopting different assumptions about the 
proportion of persistent HPV infection attributable to new
(versus latent) infections in older women, highlighting the high
priority that should be placed on empiric data to inform such
assumptions.
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